Gastric cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:54 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Gastric cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-and-drug-combination-for-patients-with-advanced-or-metastatic-her2-positive-gastric-or-gastroesophageal-junction-cancer/ Wed, 29 Apr 2026 15:04:42 +0000 https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-and-drug-combination-for-patients-with-advanced-or-metastatic-her2-positive-gastric-or-gastroesophageal-junction-cancer/ This clinical trial is focused on studying treatments for HER2-positive gastric or gastroesophageal junction cancer, which is a type of cancer that affects the stomach and the area where the stomach meets the esophagus. The study will explore the effectiveness of a new treatment combination involving Trastuzumab Deruxtecan (also known as Enhertu®) along with chemotherapy, with or without the addition of Pembrolizumab. The trial will compare this new combination to the current standard treatment, which includes chemotherapy and Trastuzumab, with or without Pembrolizumab.

The purpose of the study is to determine how well these treatments work in patients who have not received prior treatment for their advanced cancer. Participants will receive their treatment through an intravenous injection, which means the medication is given directly into a vein. The study will last for a period of up to 60 weeks, during which participants will be monitored regularly to assess the progress of their cancer and any side effects they may experience.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI or CT scans, to evaluate the size and spread of the cancer. The trial aims to provide valuable information on the potential benefits of the new treatment combination, which could lead to improved outcomes for patients with this type of cancer. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

]]> Study of Oxaliplatin, Nivolumab, and Trifluridine/Tipiracil for Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Cancer https://clinicaltrials.eu/trial/study-of-oxaliplatin-nivolumab-and-trifluridine-tipiracil-for-patients-with-advanced-gastric-esophageal-or-gastroesophageal-junction-cancer/ Wed, 29 Apr 2026 14:28:11 +0000 https://clinicaltrials.eu/trial/study-of-oxaliplatin-nivolumab-and-trifluridine-tipiracil-for-patients-with-advanced-gastric-esophageal-or-gastroesophageal-junction-cancer/ This clinical trial is focused on studying treatments for patients with advanced forms of cancer in the stomach, esophagus, or the area where the esophagus meets the stomach, known as the gastroesophageal junction. Specifically, it involves patients with a type of cancer called adenocarcinoma that does not have an excess of a protein called HER2. The study is comparing different combinations of medications to see which is more effective in stopping the cancer from getting worse. The medications being tested include trifluridine/tipiracil (known as Lonsurf), oxaliplatin, nivolumab, fluorouracil, levoleucovorin, folinic acid, and capecitabine. Some patients will receive a combination of these drugs, while others may receive a placebo.

The purpose of the study is to determine if the combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is better at delaying the progression of cancer compared to a regimen called FOLFOX, which includes fluorouracil, oxaliplatin, and folinic acid, with or without nivolumab. The study will follow patients over a period to monitor how their cancer responds to the treatment and to assess their overall health and quality of life. Patients will receive their assigned treatment and will be regularly monitored by healthcare professionals to track the progress of their disease and any side effects they may experience.

This trial aims to provide valuable information on the effectiveness and safety of these treatment combinations for patients with advanced gastric, esophageal, or gastroesophageal junction cancer. The results could help improve treatment options for these patients in the future.

]]>